Loading patent…
AssigneesSK Chemicals Co., Ltd., Standigm Inc.
InventorsSoo Min LEE, Jong-ln KIM, Nam-Jin GU, Jeong-Hoon KIM, Dae Hee HAN, Hee Jung KOO
Estimating the term…
A composition for preventing or treating a TNF-α-related disease is disclosed. The composition includes hydroflumethiazide or a pharmaceutically acceptable salt thereof as an active ingredient. The composition can effectively inhibit the expression or activity of TNF-α and exhibits an excellent treatment effect compared to methotrexate (MTX) or hydroxychloroquine (HCQ), which are rheumatoid arthritis treatment agents currently on the market, and, thus, can be effectively used for prevention or treatment of a TNF-α-related disease.
1-11. (canceled)
A method for preventing or treating a TNF-α-related disease in a subject in need thereof, the method comprising administering, to the subject, an effective amount of a composition comprising hydroflumethiazide or a pharmaceutically acceptable salt thereof as an active ingredient.
A method of inhibiting expression or activity of TNF-α in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition comprising hydroflumethiazide or a pharmaceutically acceptable salt thereof as an active ingredient.
Dependencies are inferred from the claim text.